Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Relacorilant Plus Nab-Paclitaxel Demonstrates OS Advantage in Recurrent, Platinum-Resistant Ovarian Cancer

August 7th 2023

Treatment with intermittent or continuous doses of relacorilant in combination with nab-paclitaxel resulted in an overall survival benefit compared with nab-paclitaxel monotherapy, but failed to demonstrate an improvement in progression-free survival in patients with recurrent, platinum-resistant ovarian cancer.

Investigation of Ubamatamab With or Without Cemiplimab Continues in Recurrent Ovarian Cancer

August 3rd 2023

The preliminary efficacy, safety, and optimal dose of the MUC16xCD3 bispecific antibody ubamatamab alone or in combination with cemiplimab-rwlc continues to be explored in patients with advanced platinum-resistant ovarian cancer in the phase 2 portion of an ongoing, first-in-human, phase 1/2 study.

Batiraxcept Plus Paclitaxel Misses PFS End Point in Platinum-Resistant Ovarian Cancer

August 3rd 2023

The addition of batiraxcept to paclitaxel did not significantly improve progression-free survival compared with paclitaxel alone in a prespecified subset of patients with platinum-resistant ovarian cancer who were not previously exposed to bevacizumab, missing the primary end point of the phase 3 AXLerate-OC trial.

KEYNOTE-775: Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer

August 3rd 2023

The expert panel reviews the KEYNOTE-775 trial, which focused on lenvatinib and pembrolizumab in advanced endometrial cancer.

The PHAEDRA Study and Clinical Trial Landscape in Endometrial Cancer

August 3rd 2023

A panel of gynecologic oncologists review the PHAEDRA study and discuss the overall treatment landscape for endometrial cancer.

Intravenous PRGN-3005 Plus Lymphodepletion Shows Early Promise in Ovarian Cancer

August 2nd 2023

Mary “Nora” Disis, MD, expands on key findings from the phase 1/1b study of PRGN-3005, discusses next steps for the trial, and explains how this research aids efforts to effectively utilize CAR T-cell therapy in ovarian cancer and other solid tumors.

Dr Moore on Investigating Ubamatamab Plus Cemiplimab in Recurrent Ovarian Cancer

July 29th 2023

Kathleen N. Moore, MD, MS, discusses the investigation of ubamatamab alone or in combination with cemiplimab in patients with recurrent ovarian cancer.

Dr Growdon on the Withdrawal of Later-Line Indication For Olaparib in BRCA-Mutated Ovarian Cancer

July 28th 2023

Whitfield B. Growdon, MD, expands on the FDA’s decision to withdraw the later-line indication of olaparib for patients with BRCA-mutated ovarian cancer.

Upifitamab Rilsodotin Fails to Meet ORR End Point in NaPi2b+ Platinum-Resistant Ovarian Cancer

July 27th 2023

The phase 1/2 UPLIFT trial evaluating the antibody-drug conjugate upifitamab rilsodotin in patients with platinum-resistant ovarian cancer failed to meet its primary end point of investigator-assessed overall response rate in the NaPi2b-positive population.

NRG-GY018 and RUBY Trials in Endometrial Cancer

July 27th 2023

Experts on endometrial cancer review the NRG-GY018 and RUBY clinical trials.

Recently Presented Data on Endometrial Cancer

July 27th 2023

The expert panel switches its focus to endometrial cancer and discusses recent data from clinical trials.

ENB-003 Plus Pembrolizumab Elicits Safety, Activity in Ovarian Cancer and Other Advanced, Refractory Solid Tumors

July 20th 2023

Treatment with the combination of ENB-003 and pembrolizumab was well tolerated and produced preliminary signs of clinical activity in patients with platinum-refractory or -resistant, microsatellite stable ovarian cancer, and those with other advanced refractory solid tumors.

MIRASOL Trial: Mirvetuximab in Platinum-Resistant Ovarian Cancer

July 20th 2023

Expert gynecologic oncologists react to data from the MIRASOL trial, which studied mirvetuximab in patients with platinum-resistant ovarian cancer.

Ongoing Trials on Maintenance Therapy in Recurrent Ovarian Cancer

July 20th 2023

A panel of experts on ovarian cancer review ongoing trials on maintenance therapies for recurrent ovarian cancer.

Westin Highlights Key Clinical Trial Updates from ASCO 2023 in Ovarian Cancer and Gynecologic Oncology

July 18th 2023

Shannon Westin, MD, MPH, FACOG, expands on key clinical trial updates in gynecologic oncology shared at the 2023 ASCO Annual Meeting and highlights what she is looking forward to seeing in the future of care for patients with gynecologic malignancies.

Recent Data for PARP Inhibitors in Recurrent Ovarian Cancer

July 13th 2023

A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.

Efficacy of Subsequent Therapies in Advanced Ovarian Cancer

July 13th 2023

Ovarian cancer experts review clinical trial data on the efficacy of later-line therapies in advanced ovarian cancer.

Immuno-Oncology Approaches Continue to Advance Across Gynecologic Cancers

July 11th 2023

Michael J. Birrer, MD, PhD, highlights the effect of improved molecular characterization in endometrial cancer, the clinical significance of the KEYNOTE-775 trial, and recent changes in the frontline treatment landscape in advanced endometrial cancer.

Dr Williams on Frontline Niraparib Maintenance Therapy in Ovarian Cancer

July 7th 2023

Heather R. Williams, MD, discusses findings from the phase 3 PRIMA trial in patients with ovarian cancer.

Recent Data on PARP Inhibitors as First-Line Maintenance in Ovarian Cancer

July 6th 2023

A comprehensive overview of recent clinical trial data on PARP inhibitors in the first-line maintenance setting in ovarian cancer presented at ASCO 2023.